Cart
sales@molnova.com
MK-3577
CAS No. 1019112-29-8
MK-3577( MK 3577 | MK3577 )
Catalog No. M10091 CAS No. 1019112-29-8
A potent, oral active glucagon receptor antagonist blocking the glucagon effect for the treatment of T2DM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1143 | Get Quote |
|
| 50MG | 2322 | Get Quote |
|
| 100MG | 3060 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMK-3577
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, oral active glucagon receptor antagonist blocking the glucagon effect for the treatment of T2DM.
-
DescriptionA potent, oral active glucagon receptor antagonist blocking the glucagon effect for the treatment of T2DM; inhibits glucagon-mediated cAMP increases in CHO cells expressing the human glucagon receptor with IC50 of 8.3 nM.Diabetes Phase 2 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsMK 3577 | MK3577
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research AreaMetabolic Disease
-
IndicationDiabetes
Chemical Information
-
CAS Number1019112-29-8
-
Formula Weight521.03
-
Molecular FormulaC30H30ClFN2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)C(C2=CC=C(C=C2)Cl)C3=CNC4=C3C=C(C=C4F)C
-
Chemical Name3-(4-((1R,2S)-1-(4-chlorophenyl)-1-(7-fluoro-5-methyl-1H-indol-3-yl)pentan-2-yl)benzamido)propanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Peng JZ, et al. AAPS J. 2014 Nov;16(6):1259-70.
molnova catalog
related products
-
V-0219
V-0219 is a positive allosteric modulator of GLP-1 and can be used in studies about obesity-associated diabetes.
-
GLP-1(7-37)
GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells.
-
Semaglutide Acetate
Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.
